ASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
- Abstract 62342026-09-03 · 16:30 CT · Arie Crown TheaterReal-world effectiveness of Keytruda vs standard of care in RCCS. Modi, P. Schmid, L. Paz-Ares, et al. · Mayo ClinicRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
- Abstract 66062026-09-02 · 18:45 CT · S406Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-999 study)J. Cortes, E. Winer, N. Rizvi · Institut Gustave RoussyRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
- Abstract 62372026-09-03 · 21:30 CT · Hall B1CheckMate-35: Opdivo (nivolumab) maintenance in RCCM.C. Garassino, N. Rizvi · Vall d'Hebron Institute of OncologyRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
- Abstract 68352026-09-05 · 14:00 CT · S100ALong-term follow-up of Opdivo maintenance for RCC: CheckMate-800R. Herbst, G. Curigliano, M.C. Garassino, et al. · Peter MacCallum Cancer CentreRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
- Abstract 63662026-09-04 · 20:00 CT · Hall B1Quality of life outcomes with Opdivo in patients with RCCS. Peters, H. Rugo, E. Winer, et al. · National Cancer Center JapanRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
- Abstract 68152026-09-04 · 21:30 CT · S406Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-122 study)M. Krop, S. Antonia · Memorial Sloan Kettering Cancer CenterRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
- Abstract 64602026-09-02 · 19:00 CT · Arie Crown TheaterCheckMate-129: Opdivo (nivolumab) 1L in RCCJ. Brahmer, N. Rizvi, S. Modi, et al. · University of ChicagoRapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.